BCDANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BioCardia, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.90−0.02 (-2.46%)
Close on Oct 19, 2026
- Market cap
- $10.85M
- P/E (TTM)
- –
- Dividend yield
- –
BioCardia statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | BioCardia | Industry median |
|---|---|---|
| Market Cap | $13.59M | $166.30M |
| Enterprise Value | $9.47M | $88.19M |
| PB Ratio | 5.03 | 2.03 |
| P/TBV Ratio | 5.03 | 2.29 |
Income (trailing twelve months)
| Measure | BioCardia | Industry median |
|---|---|---|
| Operating Income | -$7.39M | -$21.40M |
| Net Income | -$7.34M | -$22.46M |
| EBITDA | -$7.38M | -$16.91M |
| EPS (Diluted) | -$0.77 | -$0.83 |
Returns
| Measure | BioCardia | Industry median |
|---|---|---|
| Return on Equity (ROE) | -1803.2% | -53.2% |
| Return on Assets (ROA) | -214.5% | -40.9% |
| Return on Capital Employed (ROCE) | -273.7% | -38.1% |
Balance sheet
| Measure | BioCardia | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $4.12M | $61.43M |
| Net Cash (Debt) | $4.12M | $15.35M |
| Net Cash Per Share | $0.27 | $0.66 |
| Equity (Book Value) | $2.70M | $49.09M |
| Book Value Per Share | $0.18 | $1.37 |
| Tangible Book Value | $2.70M | $23.52M |
| Working Capital | $2.24M | $76.81M |
Financial position
| Measure | BioCardia | Industry median |
|---|---|---|
| Current Ratio | 2.09 | 3.34 |
| Quick Ratio | 2.02 | 2.44 |
Cash flow (trailing twelve months)
| Measure | BioCardia | Industry median |
|---|---|---|
| Operating Cash Flow | -$7.56M | -$12.35M |
| Capital Expenditures | -$9.00K | -$1.08M |
| Free Cash Flow | -$7.57M | -$20.22M |
| FCF Per Share | -$0.50 | -$0.42 |
Efficiency
| Measure | BioCardia | Industry median |
|---|---|---|
| Profits Per Employee | -$349.48K | -$703.34K |
| Employee Count | 21 | 74 |
Dividends and yields
| Measure | BioCardia | Industry median |
|---|---|---|
| Earnings Yield | -54.0% | -23.3% |
| FCF Yield | -55.7% | -8.72% |
| Buyback Yield | -89.0% | -0.59% |
| Shareholder Yield | -89.0% | 0.00% |
Shares
| Measure | BioCardia | Industry median |
|---|---|---|
| Shares Outstanding | 15,138,800 | 58,127,000 |
| Shares Change (YoY) | 133.0% | 10.9% |
| Shares Change (QoQ) | 37.0% | 0.54% |
| Float | 13,371,600 | 49,136,700 |
| Shares Held by Insiders | 11.7% | 11.6% |
| Shares Held by Institutions | 8.81% | 59.4% |
Taxes
| Measure | BioCardia | Industry median |
|---|---|---|
| Income Tax | $0 | $79.87K |
Scores
| Measure | BioCardia | Industry median |
|---|---|---|
| Altman Z-Score | -51.30 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from BioCardia's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.